Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 16/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119752 | 0.83 | ALDH1A1 (0.43) | TSPODYRK1AL3MBTL1 | |
| SCHEMBL6047803 | 0.82 | POLB (0.44) | TSPOL3MBTL1 | |
| SCHEMBL4110311 | 0.81 | ALDH1A1 (0.46) | TSPODYRK1AL3MBTL1 | |
| SCHEMBL13844056 | 0.79 | ELANE (0.39) | L3MBTL1 | |
| SCHEMBL4580316 | 0.79 | L3MBTL1 (0.37) | TSPODYRK1AL3MBTL1 | |
| SCHEMBL4696696 | 0.79 | MTNR1A (0.40) | TSPOL3MBTL1 | |
| SCHEMBL13844071 | 0.77 | ALDH1A1 (0.37) | DYRK1AL3MBTL1 | |
| SCHEMBL4019852 | 0.77 | L3MBTL1 (0.36) | DYRK1AL3MBTL1 | |
| SCHEMBL4307618 | 0.77 | MAPT (0.41) | L3MBTL1 | |
| SCHEMBL6047777 | 0.77 | L3MBTL1 (0.40) | TSPOL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293558-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | claimed |
| EP-1802299-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044425-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20070293558-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| EP-1802299-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044425-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293558-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNH2, KCNJ11, KCNN1 | TSPO 936/4885DYRK1A 4545/4885PSEN1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.